Advanced Biomed Inc. 8-K
Accession 0001213900-26-006281
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 5:00 PM ET
Size
191.3 KB
Accession
0001213900-26-006281
Research Summary
AI-generated summary of this filing
Advanced Biomed Inc. Appeals Nasdaq Delisting; Reverse Stock Split Planned
What Happened Advanced Biomed Inc. (ADVB) filed an 8-K on January 21, 2026 reporting that it has appealed a Nasdaq Staff determination to delist its common stock for failure to meet the $1.00 minimum bid-price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq first notified the company on July 18, 2025 and gave a 180-day compliance period that ended January 14, 2026; the company did not regain compliance. Nasdaq scheduled suspension/delisting action unless the company appealed; ADVB submitted a hearing request on January 21, 2026, which stayed the suspension pending a Hearings Panel decision. The company plans to present a compliance plan to the Panel that includes a stockholder-approved reverse stock split (approved January 12, 2026) expected to become effective on or after February 13, 2026.
Key Details
- Nasdaq rule at issue: Listing Rule 5550(a)(2) — minimum $1.00 bid price.
- Notice timeline: initial notice July 18, 2025; 180-day compliance period ended Jan 14, 2026; delisting notice dated Jan 16, 2026 (suspension scheduled Jan 27, 2026 unless appealed).
- Company action: hearing request filed Jan 21, 2026 (stays suspension); reverse stock split approved by stockholders Jan 12, 2026, expected effective on/after Feb 13, 2026.
- Filing includes standard forward-looking statement caution — no assurance the Panel will grant continued listing or that compliance will be achieved.
Why It Matters For investors, the appeal and planned reverse split are attempts to avoid delisting and restore compliance with Nasdaq’s $1 bid-price rule. If successful, continued Nasdaq listing preserves greater liquidity, visibility and investor access. If the Panel denies continued listing or the company fails to evidence compliance, ADVB could be suspended or moved off Nasdaq (potentially to OTC markets), which typically reduces trading volume and may hurt share value and investor exit options. The reverse split may raise the per-share price mathematically but does not guarantee sustained compliance or improved fundamentals.
Documents
- 8-Kea027358501-8k_advanced.htmPrimary
CURRENT REPORT
- EX-101.SCHadvb-20260116.xsd
XBRL SCHEMA FILE
- EX-101.LABadvb-20260116_lab.xml
XBRL LABEL FILE
- EX-101.PREadvb-20260116_pre.xml
XBRL PRESENTATION FILE
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0001213900-26-006281-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLea027358501-8k_advanced_htm.xml
IDEA: XBRL DOCUMENT
Issuer
Advanced Biomed Inc.
CIK 0001941029
Related Parties
1- filerCIK 0001941029
Filing Metadata
- Form type
- 8-K
- Filed
- Jan 20, 7:00 PM ET
- Accepted
- Jan 21, 5:00 PM ET
- Size
- 191.3 KB